Sorrento Therapeutics (0L85) Ratios
Sorrento Therapeutics Ratios
GB:0L85's free cash flow for Q2 2023 was $-55.80M. For the 2023 fiscal year, GB:0L85's free cash flow was decreased by $-140.00K and operating cash flow was $-55.66M. See a summary of the company’s cash flow.
| Ratios | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.29 | 1.24 | 0.89 | 0.59 | 2.91 |
| Quick Ratio | 0.26 | 1.18 | 0.87 | 0.56 | 2.91 |
| Cash Ratio | 0.07 | 0.26 | 0.59 | 0.20 | 2.73 |
| Solvency Ratio | -1.13 | -0.67 | -0.72 | -0.66 | -0.42 |
| Operating Cash Flow Ratio | -0.90 | -2.02 | -1.65 | -1.50 | -1.81 |
| Short-Term Operating Cash Flow Coverage | -18.04 | -8.81 | -6.87 | -4.37 | -11.01 |
| Net Current Asset Value | $ -398.14M | $ -443.70M | $ -308.86M | $ -457.29M | $ -287.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.34 | 0.32 | 0.53 | 0.35 |
| Debt-to-Equity Ratio | -7.23 | 3.02 | 1.03 | 3.74 | 1.11 |
| Debt-to-Capital Ratio | 1.16 | 0.75 | 0.51 | 0.79 | 0.53 |
| Long-Term Debt-to-Capital Ratio | 36.44 | 0.58 | 0.36 | 0.72 | 0.52 |
| Financial Leverage Ratio | -25.41 | 8.82 | 3.24 | 7.10 | 3.22 |
| Debt Service Coverage Ratio | -21.62 | -9.54 | -6.31 | -4.07 | -2.08 |
| Interest Coverage Ratio | -58.82 | -36.00 | -9.99 | -5.40 | -2.25 |
| Debt to Market Cap | 9.53 | 10.40 | 7.36 | 50.25 | 91.57 |
| Interest Debt Per Share | 0.34 | 0.84 | 0.82 | 2.35 | 2.74 |
| Net Debt to EBITDA | -0.21 | -0.46 | -0.41 | -0.88 | -0.44 |
| Profitability Margins | |||||
| Gross Profit Margin | 46.77% | 75.37% | 75.14% | 61.07% | 52.49% |
| EBIT Margin | -880.30% | -854.95% | -726.31% | -1032.48% | -736.80% |
| EBITDA Margin | -859.22% | -824.11% | -689.47% | -981.15% | -694.08% |
| Operating Profit Margin | -802.55% | -695.68% | -503.99% | -620.97% | -610.94% |
| Pretax Profit Margin | -893.95% | -874.28% | -791.34% | -1143.98% | -1008.73% |
| Net Profit Margin | -911.60% | -810.93% | -746.41% | -1142.48% | -960.41% |
| Continuous Operations Profit Margin | -890.10% | -810.93% | -786.30% | -1142.48% | -979.13% |
| Net Income Per EBT | 101.98% | 92.75% | 94.32% | 99.87% | 95.21% |
| EBT Per EBIT | 111.39% | 125.67% | 157.01% | 184.23% | 165.11% |
| Return on Assets (ROA) | -121.15% | -61.74% | -55.70% | -64.40% | -30.17% |
| Return on Equity (ROE) | 3078.97% | -544.79% | -180.72% | -456.94% | -97.17% |
| Return on Capital Employed (ROCE) | -348.00% | -66.27% | -45.87% | -44.12% | -21.12% |
| Return on Invested Capital (ROIC) | -286.80% | -57.00% | -42.95% | -40.16% | -20.16% |
| Return on Tangible Assets | -224.06% | -120.65% | -71.30% | -78.75% | -35.70% |
| Earnings Yield | -15419.19% | -3129.88% | -1902.79% | -7561.06% | -7989.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.57 | 2.83 | 2.58 | 2.17 | 4.86 |
| Payables Turnover | 0.70 | 0.48 | 0.40 | 0.44 | 0.73 |
| Inventory Turnover | 3.35 | 1.61 | 5.43 | 3.64 | 0.00 |
| Fixed Asset Turnover | 0.45 | 0.42 | 0.54 | 0.41 | 0.87 |
| Asset Turnover | 0.13 | 0.08 | 0.07 | 0.06 | 0.03 |
| Working Capital Turnover Ratio | -0.63 | 4.54 | -1.38 | 0.89 | 0.62 |
| Cash Conversion Cycle | -267.47 | -411.70 | -698.44 | -555.33 | -425.79 |
| Days of Sales Outstanding | 142.13 | 129.12 | 141.54 | 168.53 | 75.07 |
| Days of Inventory Outstanding | 108.85 | 227.05 | 67.23 | 100.28 | 0.00 |
| Days of Payables Outstanding | 518.44 | 767.87 | 907.21 | 824.14 | 500.86 |
| Operating Cycle | 250.98 | 356.17 | 208.78 | 268.81 | 75.07 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.70 | -0.96 | -0.69 | -1.23 | -1.05 |
| Free Cash Flow Per Share | -0.73 | -0.99 | -0.86 | -1.31 | -1.25 |
| Dividend Paid and CapEx Coverage Ratio | -21.52 | -31.77 | -4.25 | -15.12 | -5.27 |
| Capital Expenditure Coverage Ratio | -21.52 | -31.77 | -4.25 | -15.12 | -5.27 |
| Operating Cash Flow Coverage Ratio | -2.18 | -1.19 | -0.94 | -0.59 | -0.48 |
| Operating Cash Flow to Sales Ratio | -4.68 | -5.33 | -3.99 | -5.50 | -5.27 |
| Free Cash Flow Yield | -8277.34% | -2120.76% | -1256.68% | -3883.42% | -5219.11% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.01 | -0.03 | -0.05 | -0.01 | -0.01 |
| Price-to-Sales (P/S) Ratio | 0.06 | 0.26 | 0.39 | 0.15 | 0.12 |
| Price-to-Book (P/B) Ratio | -0.20 | 0.17 | 0.09 | 0.06 | 0.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.01 | -0.05 | -0.08 | -0.03 | -0.02 |
| Price-to-Operating Cash Flow Ratio | -0.01 | -0.05 | -0.10 | -0.03 | -0.02 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 |
| Enterprise Value Multiple | -0.21 | -0.49 | -0.47 | -0.90 | -0.46 |
| Enterprise Value | 114.59M | 214.62M | 128.61M | 276.33M | 67.50M |
| EV to EBITDA | -0.21 | -0.49 | -0.47 | -0.90 | -0.46 |
| EV to Sales | 1.82 | 4.06 | 3.22 | 8.79 | 3.19 |
| EV to Free Cash Flow | -0.37 | -0.74 | -0.65 | -1.50 | -0.51 |
| EV to Operating Cash Flow | -0.39 | -0.76 | -0.81 | -1.60 | -0.60 |
| Tangible Book Value Per Share | -0.57 | -0.89 | 0.10 | -0.49 | 0.97 |
| Shareholders’ Equity Per Share | -0.04 | 0.27 | 0.72 | 0.56 | 1.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.07 | 0.01 | 0.00 | 0.03 |
| Revenue Per Share | 0.15 | 0.18 | 0.17 | 0.22 | 0.20 |
| Net Income Per Share | -1.37 | -1.46 | -1.30 | -2.56 | -1.92 |
| Tax Burden | 1.02 | 0.93 | 0.94 | 1.00 | 0.95 |
| Interest Burden | 1.02 | 1.02 | 1.09 | 1.11 | 1.37 |
| Research & Development to Revenue | 3.52 | 3.91 | 2.78 | 3.40 | 3.63 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 |
| Stock-Based Compensation to Revenue | 1.19 | 1.70 | 0.79 | 0.40 | 0.00 |
| Income Quality | 0.51 | 0.66 | 0.51 | 0.48 | 0.55 |
Currency in USD
